Daraxonrasib vs ERAS-0015
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pancreatic Ductal Adenocarcinoma
Shared mechanism: pan-RAS · full Pancreatic Ductal Adenocarcinoma pipeline
Daraxonrasib · Rasonque
Marketed by Revolution Medicines and partners
NCT06625320 · Phase 3 · active, not recruiting
Patients were randomly assigned to daraxonrasib or chemotherapy, but patients and doctors knew which treatment was given. The primary endpoints, overall survival and progression read by a blinded independent central reviewer, cannot be changed by that knowledge, and both improved significantly with daraxonrasib (overall survival hazard ratio 0.40, P<0.001).
Next expected readout: December 2026 · NCT06040541 (registry estimate)
No aligned efficacy figure on record for this race.
ERAS-0015
Developed by Erasca and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2031 · NCT07897734 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Pancreatic Ductal Adenocarcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Daraxonrasib: no structured comparison results are available for Pancreatic Ductal Adenocarcinoma.
ERAS-0015: no structured comparison results are available for Pancreatic Ductal Adenocarcinoma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Daraxonrasib's landscape · ERAS-0015's landscape